A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 01090
- Allgemeines Krankenhaus der Stadt Wien
-
-
-
-
-
Creteil, France, 94010
- Centre Hospitalier Universitaire Henri Mondor
-
Lille, France, 59037
- Centre Hospitalier Regional Universitaire (Chru) de Lille
-
-
-
-
-
Milan, Italy, 20122
- Fondazione Irccs Ca Granda Ospedale Maggiore
-
Napoli, Italy, 80131
- UNIVERSIT� DI NAPOLI FEDERICO II
-
Novara, Italy, 28100
- AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARIT� DI NOVARA
-
-
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10021
- Weill Medical College of Cornell University
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- University Health System Inc., Dba the University of Tn Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of AIHA based on the presence of hemolytic anemia and serological evidence of anti-erythrocyte antibodies, detectable by the direct antiglobulin test.
- Participants who have disease progression after treatment with standard therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.
- Hemoglobin 7 to 10 g/dL.
- No evidence of a lymphoproliferative malignancy or other autoimmune-related underlying conditions.
- Eastern Cooperative Oncology Group performance status of 0 to 2.
- Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Concurrent conditions and history of other protocol-specified diseases.
- ANC < 1.5 × 10^9/L.
- Platelet count < 100 × 10^9/L.
- Severely impaired liver function.
- Impaired renal function with estimated creatinine clearance less than 45 mL/min.
- Anti-phospholipid antibodies positive or elevated anti-streptolysin antibodies.
- Positive serology test results for hepatitis B surface antigen or core antibody, or hepatitis C virus antibody with detectable RNA at screening, consistent with active or chronic infection.
- Known HIV infection or positivity on immunoassay.
- History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful.
- Known hypersensitivity or severe reaction to parsaclisib or its excipients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Parsaclisib 1 mg QD
Parsaclisib at 1 milligram (mg) once daily (QD) for 12 weeks followed by extension period, with a dose-increase option (to 2.5 mg QD) at Week 6 for participants who fulfill dose increase criteria.
|
Parsaclisib administered orally.
Other Names:
|
|
Experimental: Parsaclisib 2.5 mg QD
Parsaclisib at 2.5 mg QD for 12 weeks followed by extension period.
|
Parsaclisib administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Attaining a Complete Response at Any Visit From Week 6 to Week 12
Time Frame: Week 6 to Week 12
|
A complete response was defined as hemoglobin >12 grams per deciliter (g/dL) not attributed to a transfusion effect and the normalization of hemolytic markers.
No transfusion effect was defined as > 1 week since the last transfusion.
|
Week 6 to Week 12
|
|
Percentage of Participants Attaining a Partial Response at Any Visit From Week 6 to Week 12
Time Frame: Week 6 to Week 12
|
A partial response was defined as hemoglobin 10-12 g/dL or at least a 2 g/dL increase from Baseline not attributed to a transfusion effect and the normalization of hemolytic markers.
No transfusion effect was defined as > 1 week since the last transfusion.
|
Week 6 to Week 12
|
|
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Time Frame: up to 1638 days
|
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent.
Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy, or required changes in the study drug.
Anemia and transfusions should not have been reported as AEs unless they represented a clinically meaningful decrease from Baseline in hemoglobin.
A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug.
|
up to 1638 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Cmax of Parsaclisib
Time Frame: predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
Cmax was defined as the maximum observed concentration.
Participants in Cohort 1 were not eligible to receive parsaclisib 2.5 mg at Week 2.
|
predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
|
Mean Tmax of Parsaclisib
Time Frame: predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
tmax was defined as the time to the maximum concentration.
Participants in Cohort 1 were not eligible to receive parsaclisib 2.5 mg at Week 2.
|
predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
|
Mean Cmin of Parsaclisib
Time Frame: predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
Cmin was defined as the minimum observed concentration over the dose interval.
Participants in Cohort 1 were not eligible to receive parsaclisib 2.5 mg at Week 2.
|
predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
|
Mean AUC0-4 of Parsaclisib
Time Frame: predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
AUC0-4 was defined as the area under the concentration-time curve from time = 0 to 4 hours postdose.
Participants in Cohort 1 were not eligible to receive parsaclisib 2.5 mg at Week 2.
|
predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
|
Mean AUC0-t of Parsaclisib
Time Frame: predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
AUC0-t was defined as the area under the concentration-time curve from time = 0 to the last measureable concentration at time = t.
Participants in Cohort 1 were not eligible to receive parsaclisib 2.5 mg at Week 2.
|
predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
|
Mean Clast of Parsaclisib
Time Frame: predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
Clast was defined as the last measurable concentration (above the quantification limit).
Participants in Cohort 1 were not eligible to receive parsaclisib 2.5 mg at Week 2.
|
predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
|
Mean Tlast of Parsaclisib
Time Frame: predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
Tlast was defined as the time of the last measurable concentration (above the quantification limit).
Participants in Cohort 1 were not eligible to receive parsaclisib 2.5 mg at Week 2.
|
predose at Weeks 1 and 12; predose and 1, 2, and 4 hours postdose at Weeks 2 and 8
|
|
Percentage of Participants Attaining a Complete Response During Post-Baseline Visits
Time Frame: up to 1638 days
|
A complete response was defined as hemoglobin >12 g/dL) not attributed to a transfusion effect and the normalization of hemolytic markers.
No transfusion effect was defined as > 1 week since the last transfusion.
|
up to 1638 days
|
|
Percentage of Participants Attaining a Partial Response During Post-Baseline Visits
Time Frame: up to 1638 days
|
A partial response was defined as hemoglobin 10-12 g/dL or at least a 2 g/dL increase from Baseline not attributed to a transfusion effect and the normalization of hemolytic markers.
No transfusion effect was defined as > 1 week since the last transfusion.
|
up to 1638 days
|
|
Percentage of Participants Attaining a ≥ 2 g/dL Increase in Hemoglobin From Baseline
Time Frame: up to 1638 days
|
Hemoglobin levels were assessed throughout the study.
|
up to 1638 days
|
|
Change From Baseline in Hemoglobin
Time Frame: Baseline; up to 1638 days
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline; up to 1638 days
|
|
Percentage Change From Baseline in Hemoglobin
Time Frame: Baseline; up to 1638 days
|
Percentage change from Baseline was calculated as: ([post-Baseline value minus the Baseline value] / Baseline value) x 100.
|
Baseline; up to 1638 days
|
|
Percentage of Participants Requiring Transfusions
Time Frame: Baseline; up to 1638 days
|
A participant was defined to have required a transfusion if his or her last transfusion was within 7 days of the visit date.
|
Baseline; up to 1638 days
|
|
Percentage of Participants Who Achieved Normalization of Hemoglobin, Haptoglobin, Lactate Dehydrogenase (LDH), Reticulocyte Count, Total Bilirubin, Direct Bilirubin, and Indirect Bilirubin
Time Frame: up to 1638 days
|
Normalization was determined by the Investigator based on normal ranges for the clinical reference laboratory.
|
up to 1638 days
|
|
Percentage of Participants Requiring a Prednisone Dose Change (Increase or Decrease)
Time Frame: up to 1638 days
|
Prednisone use was monitored throughout the study.
|
up to 1638 days
|
|
Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Subscale Scores
Time Frame: Baseline; up to 1638 days
|
The FACIT-F subscale is a 13-item instrument designed to assess fatigue/tiredness and its impact on daily activities and functioning in a number of chronic diseases.
Participants were asked to respond to 13 statements that people with the illness have said are important on the following scale: 0, not at all; 1, a little bit; 2, somewhat; 3, quite a bit; 4, very much.
Participants were asked to indicate the response as it applied to the last 7 days.
The total fatigue subscale score ranges from 0 to 52; a higher score indicates more severe impact on daily activities and functioning.
|
Baseline; up to 1638 days
|
|
Change From Baseline in Reticulocyte Count
Time Frame: Baseline; up to 1638 days
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value
|
Baseline; up to 1638 days
|
|
Change From Baseline in Cardiolipin Immunoglobulin G (IgG) Antibody and Cardiolipin Immunoglobulin M (IgM) Antibody
Time Frame: Baseline; Week 12
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline; Week 12
|
|
Change From Baseline in Cold Hemagglutinin Levels
Time Frame: Baseline; Week 12
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline; Week 12
|
|
Change From Baseline in Haptoglobin, Total Bilirubin, Direct Bilirubin, and Indirect Bilirubin
Time Frame: Baseline; up to 1638 days
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline; up to 1638 days
|
|
Change From Baseline in Lactate Dehydrogenase (LDH)
Time Frame: Baseline; up to 1638 days
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline; up to 1638 days
|
|
Change From Baseline in CH50
Time Frame: Baseline; up to 1638 days
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline; up to 1638 days
|
|
Change From Baseline in Complement C3 and Complement C4
Time Frame: Baseline; up to 1638 days
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline; up to 1638 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Kathleen Butler, MD, Incyte Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- INCB 50465-206
- Parsaclisib (Other Identifier: Incyte Corporation)
- 2017-003652-22 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.